Pacira制药 PCRX 深 沪
等待开盘 11-04 09:30:00 美东时间
22.19
+0.810
+3.79%
华盛通- 最 高22.74
- 今 开21.37
- 成交量 140.03万股
- 最 低 21.37
- 昨 收 21.38
- 总市值 10.28亿
- 52周最高 27.64
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 16.00
- 委 比 31.55%
- 总股本 4630.47万
- 历史最高 121.95
- 量 比 2.78
- 振 幅 6.41%
- 历史最低 6.51
- 每 手 1
- 风险率 2.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
Pacira BioSciences announced updated three-year results from its Phase 1 trial of PCRX-201, a gene therapy for knee osteoarthritis, showing sustained improvements in pain, stiffness, and function for up to 156 weeks after a single injection. The treatment, based on a high-capacity adenovirus vector platform, boosts interleukin-1 receptor antagonist production to reduce chronic inflammation. Results demonstrated safety and efficacy across all pati...
10-28 12:00
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
Pacira BioSciences announced that real-world evidence on the clinical effectiveness and economic benefits of EXPAREL® (bupivacaine liposome injectable suspension) will be presented at the AMCP Nexus 2025 Annual Meeting. The presentations include findings from the company's IGOR registry, showcasing improved pain management, reduced opioid use, and shorter hospital stays following knee arthroplasty, as well as cost savings in ambulatory surgical c...
10-23 12:00
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
Pacira BioSciences received a Paragraph IV Certification Notice Letter from The WhiteOak Group, a subsidiary of Zhejiang Haichang Biotechnology, challenging the validity of 19 EXPAREL patents. WhiteOak filed an ANDA for a generic version of EXPAREL, claiming the patents are invalid or不会被侵犯. Pacira plans to defend its intellectual property and may file a lawsuit within 45 days, which could delay FDA approval of WhiteOak's product for up to 30 mont...
10-21 12:30
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
Pacira BioSciences announced that Phase 1 data for PCRX-201, a novel gene therapy for knee osteoarthritis, will be presented at ACR Convergence 2025. PCRX-201, utilizing a high-capacity adenovirus vector, showed sustained efficacy and safety in reducing pain and improving function, with a well-tolerated safety profile. The company acquired GQ Bio's HCAd platform, enabling larger gene delivery and cost-efficient production. Pacira's commitment to ...
10-20 20:01
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Propanc Biopharma enters into a $100 million strategic financing agreement with Hexstone Capital to accelerate clinical development and expand its digital asset treasury. The deal includes Series C Preferred Stock with a 280% premium over closing price, and up to $99 million in potential funding via warrants. Propanc aims to grow its treasury to $100 million within a year.
10-15 12:45
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
Propanc Biopharma announced the granting of its fourth US patent for "proenzyme composition," specifically capturing a future clinical dose of its lead asset, PRP, targeting metastatic cancer. The company holds 90 patents in major jurisdictions and plans to advance PRP into a Phase 1B study. PRP, as an EMT modulator, uniquely treats cancer without severe side effects, aiming to address the global metastatic cancer market valued at $111.2 billion.
09-17 12:45
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Propanc Biopharma完成100万股普通股发行，每股4美元，筹资400万美元。股票于8月15日在纳斯达克上市，承销商为D. Boral Capital和Craft Capital Management。公司计划使用资金发展创新癌症疗法，旨在靶向癌症干细胞，尤其是胰腺、卵巢和结直肠癌。
08-19 12:30
Cleveland Browns Achieve True Circularity with PureFive™ Resin in Souvenir Cups
Cleveland Browns announce use of 100% PureFive™ resin in 2025 player souvenir cups, marking a circular plastics solution. The team, a PureZero partner with PureCycle, has worked since 2024 to improve recycling at games. The new cups, part of Churchill Container's 'Run It Back' line, feature PureCycle's innovative dissolution recycling technology, allowing up to 100% post-consumer recycled polypropylene while meeting food safety and performance st...
08-19 12:30
PharmaCorp Rx Inc. reports Q2 results
PharmaCorp Rx Inc. press release (TSXV:PCRX:CA): Q2 Net loss for the quarter reflects continued investment in corporate infrastructure and the catch-up of executive compensation deferred from 2024 Ope...
08-19 01:59
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
